ARM
26.9.2022 22:41:37 CEST | Business Wire | Press release
Arm today announced the appointment of new Board members Karen Dykstra, former Chief Financial and Administrative Officer of AOL and Jeff Sine, Co-Founder and Partner of Raine Group, effective immediately. These highly qualified leaders bring a diverse range of expertise to Arm as the company prepares for a potential public listing.
Arm Chief Executive Officer (CEO) Rene Haas said: “I extend a warm welcome to Karen and Jeff, both exceptional business leaders who will bring a depth and breadth of experience to the Arm Board.”
Arm also today announced the appointment of Jason Child as Chief Financial Officer (CFO). Child has more than 30 years of experience in leadership at high growth companies and scaling global finance functions. Child will join Arm on November 2, 2022 and lead the company’s global finance and IT organizations, reporting to Haas.
Haas added, “Jason is an experienced leader in global finance and technology. His extensive experience in financial management at public companies and IPO execution will be invaluable in preparation for a potential public listing. I look forward to working with him as part of the Arm leadership team as we continue to define the future of computing, built on Arm.”
Child will replace current CFO Inder Singh who will remain at Arm in an advisory role and assist in the transition through November before moving to a new opportunity.
Haas said, “I’d like to thank Inder for his contributions and leadership over these past few years. He has helped the company navigate many changes since joining in 2019, including building a strong organization with upgraded systems and processes in the finance, IT and cybersecurity teams. We wish him all the best moving forward.”
Child most recently served as senior vice president and CFO at Splunk from 2019. Prior to Splunk, Child held multiple CFO positions including at Groupon, which he helped to take public in 2011 and as CFO at Amazon International.
“Since its founding, Arm has had an incredible history of innovation and leadership in the semi-conductor industry,” said Child. “Arm is a world-class, category leader and I am thrilled to join as CFO during this exciting time for the company.”
About Karen Dykstra
Ms. Dykstra previously served as Chief Financial and Administrative Officer of AOL, a web portal and online service provider. Prior to AOL, she was a Partner at Plainfield Asset Management, and served as Chief Operating Officer and Chief Financial Officer of Plainfield Direct, Plainfield’s business development company. She previously spent over 25 years with Automatic Data Processing (ADP), a provider of human capital management solutions to employers, serving most recently as Chief Financial Officer. Ms. Dykstra is currently a director on the boards of VMware and Gartner, and has also served on the boards of Boston Properties, Crane and AOL.
About Jeff Sine
Mr. Sine is the Co-Founder and Partner of The Raine Group, a global merchant bank focused on technology, media and communications. Prior to founding Raine, he served as Vice Chairman and Global Head of Technology, Media & Telecom Investment Banking at UBS Investment Bank, was a Managing Director at Morgan Stanley and was an attorney at Sullivan & Cromwell in New York and London. Mr. Sine currently serves on the boards of many Raine portfolio companies and subsidiaries. He also serves on the boards of National Public Radio (NPR) (Vice-Chair), ITHAKA, Educational Testing Service (ETS) (Chair), American University and The Manhattan Theatre Club.
About Jason Child
Jason Child’s career spans 30 years across all aspects of global finance and strategy, accounting, capital markets/treasury, IPO execution and investor relations. He has extensive experience in scaling disruptive technologies within enterprise software/SaaS, e-commerce, local commerce, consumer hardware/IOT, and online residential real estate. He most recently served as senior vice-president and CFO at Splunk, a technology company specializing in application management, security and compliance, as well as business and web analytics. Before his executive leadership roles, Jason spent more than 11 years leading various global finance teams at Amazon, and served as CFO of Amazon International. Jason has served as a member of the board of directors of Coupang, Inc., an e-commerce company, since April 2022. He holds B.A. from the Foster School of Business at the University of Washington, where he currently serves on the Global Advisory Board.
About Arm
Arm technology is defining the future of computing. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 230 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, we are enabling artificial intelligence to work everywhere, and in cybersecurity, we are delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
All information is provided "as is" and without warranty or representation. This document may be shared freely, attributed and unmodified. Arm is a registered trademark of Arm Limited (or its subsidiaries). All brands or product names are the property of their respective holders. © 1995-2022 Arm Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005775/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
